Among the most notable technical achievements was the completion of the calibration of a 4,400 qubit Advantage2(TM) processor, capable of solving much larger and complex problems with faster time-to-solution than earlier generation processors.
D-Wave earned “awardable” status on the U.S. Department of Defense’s Tradewinds buying platform, gaining increased visibility with U.S. government customers.
New partnerships and collaborations include working with NTT DOCOMO, Japan Tobacco Inc., Staque and the Chicago Quantum Exchange.
D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, recently announced Q3 2024 business results, highlighting several key operational milestones and technological achievements, including new partnerships and developments in driving the adoption of quantum computing technology.
“Annealing quantum computing is continuing to drive the commercial adoption of quantum technology,” said Dr. Alan Baratz, CEO of D-Wave, in a company news release (https://ibn.fm/ZjaSa). “Organizations around the world – from Vinci Energies in Europe to NTT DOCOMO in Japan – are recognizing the…
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
SuperCom’s superior electronic monitoring (“EM”) technology is highly competitive when it comes to tracking house arrest subjects and domestic violence offenders, allowing the company to expand its client base and revenue performance this year
Israel-based SuperCom is improving law enforcement agencies’ capacity to monitor offenders on supervised release as a community-building and budget-conscious alternative to incarceration and to help reduce recidivism
The company recently reported third-quarter financial information, including data on YoY revenue growth from $20.9 million to $21.3 million in the first 9 months and $6.78 million to $6.91 million during Q3. Also, the company reported on YoY EBITDA growth from $3.7 million to $4.6 million in the first 9 months.
SuperCom’s recent client contract wins have included expansion into various states in North America, plus over $13.5 million in projects for European governments
Electronic monitoring (“EM”) technology developer SuperCom (NASDAQ: SPCB) reported the success of its international expansion initiatives recently in a Q3 earnings call that included details about increased revenue and gross profit margin.
SuperCom has developed EM technology under its PureSecurity platform, which offers competitive performance improvements over legacy services in domestic violence offender tracking, house arrest monitoring, and other…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN) announced a follow-on order from TEC Equipment for seven all-electric 2025 Bollinger B4 trucks, with revenue recognized in the current fiscal quarter. This order builds on TEC’s initial purchase of three B4 trucks in October 2024, with deliveries planned across California, Oregon, and Washington. The Class 4 B4 truck, featuring a 185-mile range and 7,394-pound payload, is designed for commercial fleets with a focus on safety and efficiency, qualifying for substantial federal and state tax incentives. Bollinger Motors has recently achieved key milestones, including EPA and CARB certifications, production launch, and agreements with major fleet operators and dealers, solidifying its position in the commercial EV market.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
McEwen Mining (NYSE: MUX) (TSX: MUX) shared promising assay results from its Grey Fox deposit within the Fox Complex in Ontario, Canada, including a highlight of 10.2 g/t gold over 11.1 meters at the Whiskey Jack zone. Geological studies reveal similarities between Grey Fox and Japan’s high-grade Hishikari Gold Mine, suggesting potential for stacked epithermal veins alongside orogenic gold zones. Current modeling identifies over 50 mineralized lenses, with 90% of Grey Fox’s 1.4-million-ounce gold resource located within 300 meters of the surface. The ongoing exploration aims to expand production and uncover deeper mineralization, with an updated resource estimate for the Fox Complex expected in Q1 2025.
McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, the company owns approximately 47.7% of McEwen Copper, which is developing the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing the share price and providing a yield. Rob McEwen, chair and chief owner, has a personal investment in the company of $220 million and takes an annual salary of $1. To learn more about the company, visit www.McEwenMining.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
Brera Holdings, an Ireland-based, international holding company with a global portfolio of men’s and women’s sports clubs, has noted a spike in Italian Serie B club and player market values between June 15, 2024, and Nov. 12, 2024
Key clubs such as Carrarese Calcio, SS Juve Stabia and Cesena FC posted a 151%, 146.7% and 143.4% increase in valuations, respectively, over the study period
According to Brera’s management, this trend highlights Serie B’s growing importance both as a developmental league and as a place where young talent thrives
It further validates the company’s commitment earlier in the year to enter the Italian Serie B football space with its exclusive letter of intent to acquire a team in the league
Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach, is encouraged by recent positive valuations across Italy’s Serie B pro football league. This follows a spike in club and player market values, based upon data from Transfermarkt, which highlights the growing interest in the sport, along with the growing importance of Serie B as a developmental league where young talent is refined and prepped for success in Serie A and beyond (https://ibn.fm/Nburg).
In its study, which evaluated data between June 15, 2024, and Nov. 12, 2024, Brera noted that several teams in Serie B saw a significant uptick in valuations. Most notably, Carrarese Calcio 1908 recorded a 151% jump, from €5.25 million to €13.18 million. SS Juve Stabia also posted a 146.7% increase in…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
SOBR Safe (NASDAQ: SOBR) (“SOBRsafe”) is a provider of next-generation transdermal alcohol screening and monitoring solutions. The company recently launched a national campaign that seeks to introduce its technology offerings – the SOBRcheck(TM) stationary alcohol screening device, the SOBRsure(TM) discreet alcohol monitoring wristband, and the SOBRsafe(TM) software platform powering reporting – to behavioral health providers and, as a result, drive sales growth into 2025. “The company aims to present its technology to over 45,000 decision-makers in the behavioral health space, having partnered with recognized leaders in public relations and digital and social media marketing,” reads an article discussing the campaign.
“We are working with national communications leaders to build the SOBRsafe brand, grow demand and gain market share,” said SOBRsafe CEO and Chairman Dave Gandini. “This effort will move us closer to improving patient outcomes and saving lives.”
About SOBRsafe(TM) Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (“SOBRcheck”) and continuous monitoring (“SOBRsure”). SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI) has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board, where he will support the advancement of the company’s IL-17 program and VHH antibody pipeline. Dr. Sadeh brings over 20 years of drug development experience, including senior leadership roles at Bristol-Myers Squibb, where he led programs in immunology, cardiovascular, and neuroscience, and was instrumental in the approval of Sotyktu for psoriasis. With a background in pulmonary and critical care from Harvard Medical School and a focus on innovative therapies addressing unmet medical needs, Dr. Sadeh expressed enthusiasm for Scinai’s bio-better approach and collaborations with institutions like Max Planck and UMG. CEO Amir Reichman emphasized Dr. Sadeh’s invaluable expertise in advancing Scinai’s mission to deliver transformative therapies.
Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Two incidents of domestic violence-related homicides in Maine help illustrate the importance of court-administered electronic monitoring programs for staving off violence between domestic partners after relationships break down
With a track record of over 50 governments and 100,000 individuals served, SuperCom is innovating advanced electronic monitoring (“EM”) solutions to establish safeguards for potential victims
SuperCom’s solution uses GPS technology to track the movements of domestic violence defendants, helping prevent further violence while also alerting law enforcement and potential victims if court-imposed boundaries are trespassed
Electronic monitoring technology developer SuperCom (NASDAQ: SPCB) provides products and services that help clients track people under their supervision. Its solutions are primarily used by police and court agencies to monitor the movements of individuals released pretrial, on probation after conviction, or on parole following incarceration.
Concerns about the incidence of domestic violence are increasingly leading to the use of EM monitoring for individuals accused of such crimes. A U.S. Department of Justice grant to research the use of EM in domestic violence cases in two locations, published in 2004, found that the use of…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN), announced a collaboration with Emerald Transportation Solutions and the Papé Group to develop a refrigerated (“reefer”) upfit for the Mullen THREE, its Class 3 all-electric truck. Designed for perishable goods transportation, the versatile Mullen THREE offers a clean top-of-rail chassis for custom upfitting, supporting payloads over 5,300 lbs. This innovative solution aligns with Mullen’s goal of delivering sustainable transportation options for industries like frozen food, grocery, and beverage delivery. Additionally, the Mullen THREE and Mullen ONE models are eligible for state and federal incentives, offering substantial cost savings for fleet operators.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Brera Holdings (NASDAQ: BREA) announced the return of The Pepito Cup, an annual soccer fan club tournament organized by Advisory Board member Giuseppe Rossi. Held on November 17, 2024, at the Waldwick Superdome in New Jersey and sponsored by the GIUSEPPE ROSSI ACADEMY, the event featured 12 teams competing in a 25-minute match elimination format, with Napoli Club NYC crowned champions. Open to the public and family-friendly, the event reflects Brera Holdings’ commitment to fostering community engagement and expanding its global sports footprint through initiatives led by influential figures like Rossi.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
McEwen Mining (NYSE: MUX) (TSX: MUX) is positioned for opportunity as artificial intelligence is rapidly reshaping the landscape of economies around the world. “Estimates indicate that generative AI alone will triple its growth to a total market value of $1.3 trillion in the next decade… As most investors know by now, there is a surge in the demand for energy-guzzling data centers that are designed to develop and train AI systems. They also know that advanced semiconductor chips are at the heart of all AI technologies. However, many haven’t considered that critical minerals, such as copper, gold and silver, are vital components of this burgeoning industry,” reads a recent article.
“McEwen Mining is well poised to benefit from the tailwinds arising from the explosive growth of the AI industry. For example, the company has a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, which is one of the world’s largest and most economically robust undeveloped copper projects.
“Given the skyrocketing demand for copper and the anticipated supply shortages in the coming decades, McEwen’s copper resource alone could be a game-changer. The ongoing geopolitical tensions and the drive to develop critical metals’ supply lines outside of those controlled by China and its allies makes the gold and silver extraction operations of McEwen Mining in the Americas better positioned to tap the AI revolution for years and decades to come.”
McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, it owns approximately 47.7% of McEwen Copper, which owns the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing its share price and providing a yield. Rob McEwen, MUX’s chairman and chief owner, has personally provided the company with $220 million and takes an annual salary of $1.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria Maccecchini, the event will highlight updates on Phase 3 studies for Parkinson’s and Alzheimer’s diseases, regulatory milestones, financial strategies, and plans for advancing neurodegenerative therapies in 2025.
Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SuperCom is an electronic monitoring (“EM”) innovator helping to establish public safety and well-being through the use of advanced technology and monitoring services for government clients that make increasing use of supervised-release programs
During a recent investor presentation at the annual LD Micro Invitational, SuperCom’s president and CEO, Ordan Trabelsi, outlined the company’s services and critical benefits to clientele, along with the company’s corresponding success with over 50 governments and 100,000 individuals served
SuperCom anticipates that its $32 million contract in Romania, largely focused on monitoring domestic violence offenders, will help boost its credibility with other European governments running monitoring programs of a similar nature
Governments worldwide are turning to electronic monitoring (“EM”) solutions as a means of sustaining public safety and reducing repeat criminal behavior while also reducing the costs associated with imprisoning individuals — a trend outlined by EM innovator SuperCom (NASDAQ: SPCB) at a recent investor LD Micro presentation. SuperCom President and CEO Ordan Trabelsi explained the competitive edge of the company’s GPS-enabled PureSecurity platform, among a narrow field of rivals, during his appearance at LD Micro’s 17th annual invitational on Oct. 30 (https://ibn.fm/XPMXE). Trabelsi participated in one-on-one interviews with potential investors over the course of the event’s three days in Southern California.
SuperCom was founded in 1988 and has a track record of serving over 50 governments and 100,000 individuals. Its CAGR is above 60%, with 73% recurring revenue and a five-year EBITDA of $4.8 million as…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent glioblastoma multiforme (“GBM”). Presented at the 29th Annual Meeting of the Society for Neuro-Oncology, the data show balanced patient demographics and safety profiles between the study arms, with Berubicin showing comparable adverse event rates and promising potential to improve overall survival (“OS”), the trial’s primary endpoint. With enrollment completed at 252 patients, CNS expects to report primary analysis data in early 2025. Berubicin holds FDA Fast Track and Orphan Drug Designations, underscoring its significance in advancing GBM treatment options.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
“In 2024, over 611,000 deaths from cancer are projected for the U.S.,” the ACA reported. “That’s more than 1,600 deaths from cancer each day.”
Calidi Biotherapeutics’ RTNova (“CLD-400”) is an innovative systemic antitumor enveloped virotherapy, designed to unlock new possibilities in cancer therapy.
RTNova offers a systemic approach that enables providers to target and treat metastatic tumors that were previously untouchable.
The American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United States, after heart disease (https://ibn.fm/ADo2Q). Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are working hard to discover more effective treatments to curb the rising numbers. Calidi recently presented key data at two prominent scientific conferences regarding its new generation of targeted antitumor virotherapies and viral vectors (https://ibn.fm/9johm).
“Over the last 30 years, the risk of dying from cancer has steadily declined, sparing some four million lives in the United States,” the ACA reported. “This downward trend can partially be explained by big wins in smoking cessation, early cancer detection and treatment advancements. Cancer incidence, however, is…
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing innovative biological products targeting inflammation and immunology (“I&I”) and offering contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices division, released its financial results for the nine months ending Sept. 30, 2024. The announcement highlights the company’s progress in advancing its I&I-focused pipeline and the expansion of its CDMO operations, showcasing its commitment to delivering high-quality biologics and fostering strategic partnerships. This update reflects Scinai’s efforts to strengthen its position in the biopharmaceutical and CDMO markets, aligning with its broader vision of growth and innovation.
Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
NetworkNewsWire Editorial Coverage: Interest in the mining sector is on the rise, fueled by growing demand for metals that are crucial to modern industries. The shift toward clean-energy technologies, including electric vehicles (EVs) and renewable energy systems, has heightened the need for critical minerals, particularly lithium, cobalt, nickel and rare earth elements (“REEs”). At the same time, traditional metals such as copper and aluminum are seeing renewed importance due to their essential roles in infrastructure and energy transmission. Gold and silver remain appealing as safe-haven assets during periods of economic uncertainty and inflation. Additionally, the global drive for decarbonization and energy efficiency is boosting demand for platinum group metals (“PGMs”), which are valued for their purity, high melting points and unique catalytic properties. These metals are integral to numerous industrial processes and play a pivotal role in autocatalysis and pollution control within the automotive industry. With potential supply disruptions from major producers and geopolitical tensions tightening the market, mining companies are well positioned for growth. One of those companies, Platinum Group Metals Ltd. (NYSE: PLG) (TSX: PTM) (Platinum Group Metals Profile), is emerging as a leader in the PGM space, due to the performance of its flagship Waterberg Project in South Africa. Platinum Group Metals joins other mining and commodity-related organizations that are focused on strengthening their foothold in the mining sector, including companies such as Endeavour Silver Corporation (Canada) (NYSE: EXK), Fortuna Mining Corp. (NYSE: FSM), New Gold Inc. (NYSE American: NGD) and…
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Brera Holdings (NASDAQ: BREA) announced the screening of The Amazing Adventures of Mr. Fenix (in the Lands of European Non-Professional Football) at the OFFSIDE FOOTBALL FILM FESTIVAL 2024 in Milan. The documentary, which celebrates the FENIX Trophy’s mission to honor non-professional football clubs with cultural and community significance, was followed by a discussion featuring co-founder Leonardo Aleotti and director Gigi Mammana. Highlighting the competition’s focus on grassroots football, the film explores how the FENIX Trophy provides an alternative to commercialized tournaments, showcasing smaller clubs’ dedication to social impact, fair play, and local pride, with the official endorsement of UEFA.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, provided an update on its Fullerton, California, battery operations, which focus on producing next-generation battery packs and modules domestically. This initiative supports Mullen’s commitment to zero emissions and reducing reliance on imported battery components. CEO and Chairman David Michery emphasized the company’s mission to transition to American-made battery technology as part of its broader sustainability goals.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
SOBRsafe (NASDAQ: SOBR), a provider of next-generation transdermal alcohol detection solutions, earlier this year began the sale of its SOBRsure(TM) wearable continuous alcohol monitoring device in Australia and New Zealand following a 90-day proof-of-concept. “This overseas milestone was made possible through an international channel partnership with Drug Testing Business Success, the leading drug and alcohol testing service provider in the region,” reads a recent article.
The piece describes the company’s excitement surrounding the new revenue stream in both countries and the opportunity to accelerate broader global growth in the U.S. and other international markets. “SOBRsafe recently issued an update on the expansion into Australia and New Zealand, reporting that courts in both countries have now approved the company’s technology for use in family law cases.” SOBRsafe’s chairman and CEO Dave Gandini expressed significance of the legal approval, empowering the company’s partner “to market to the more than 7,000 family law attorneys in the region” and giving “SOBRsafe a template for expansion into the family law vertical in the U.S.”
About SOBRsafe(TM) Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (“SOBRcheck”) and continuous monitoring (“SOBRsure”). SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
McEwen Mining (NYSE: MUX) (TSX: MUX) was featured in a recent article that discussed the evolution of artificial intelligence (“AI”), spotlighting Geoffrey Hinton’s (“the Godfather of AI”) award of the Nobel Prize in Physics alongside John Hopfield for their groundbreaking work that triggered the development of machine learning, the science behind AI as we know it today. The piece describes early work and systems compared to modern capabilities, showcasing significant requirements for current AI systems in terms of hardware such as microchips.
“Critical metals like copper, silver and gold have consequently seen rising demand to supply the rapidly growing AI industry,” the article reads. “Opportunities are being created, and numerous companies like McEwen Mining are positioned to reap the rewards of addressing this demand for ‘AI metals.’”
McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, it owns approximately 47.7% of McEwen Copper, which owns the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing its share price and providing a yield. Rob McEwen, MUX’s chairman and chief owner, has personally provided the company with $220 million and takes an annual salary of $1.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
Brera Holdings, an Ireland-based, international holding company with a global portfolio of men’s and women’s sports clubs, has reiterated its commitment to elevating Mozambique’s football landscape
Seeing as it is ranked 183/193 on the Human Development Index (“HDI”) by the United Nations Development Program (“UNDP”), Brera recognizes the huge untapped opportunities to explore new initiatives to develop talent
Since it entered this market in March 2023, Brera Tchumene FC has earned promotion to Maçambola, the country’s top-tier national league, and has since expanded its operations significantly
Brera’s management shared this and more at the Soccerex Miami 2024 event held on November 13-14 in Miami, Florida
Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach, has reiterated its commitment to elevate Mozambique’s football (soccer) landscape. Brera recognizes the vast untapped opportunity from an empowerment perspective and an economic one.
“Our vision is to not only elevate Mozambique’s football landscape but also play a crucial role in Africa’s overall football ecosystem,” noted Vasco Imparato, the CEO of Brera Tchumene FC. “We are building an operation that will attract talent, nurture excellence, and open doors for Mozambican players on the…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
Brera Holdings (NASDAQ: BREA), a publicly traded company focused on multi-club ownership of international football teams, was featured in a recent TipRanks article. The publication reads, “Brera Holdings (BREA) analyzed data from Transfermarkt, which shows that, from June 15, 2024, to Nov. 12, 2024, the market values of Italian Serie B clubs and players have surged. However, the 2024/25 season has also exposed challenges for certain teams, with declines in club valuations reflecting the competitive and financial hurdles faced by Serie B clubs in Italy. Given that Brera Holdings announced in September 2024 that it signed an exclusive letter of intent to acquire an Italian Serie B club, it is excited about the overall positive trends across the league.”
Brera Holdings is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs. For more information, visit the company’s website at www.BreraHoldings.com.
NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
Third-Party Content
The IW website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the IW Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IW or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IW does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IW providing you with this internet portal that makes accessible to you the ability to view third party content through the IW site, IW does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IW expressly disclaims liability relating to such third-party content. IW and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IW reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.investorwire.com/disclaimer.
The disclaimers on the IW website are applicable to all content provided by IW, wherever published or re-published are at: https://www.investorwire.com/disclaimer
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently achieved a significant milestone in its drug development process. In early October, the company held a meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap.
“We are now ready to move into the highly anticipated Phase 3 stage,” Maria Maccecchini, Ph.D., founder, president and CEO of Annovis Bio, was quoted as saying. “Our priority is to bring the treatment to patients as early as possible, and we are executing the next clinical trial at the highest standards to attain an expedited NDA submission.”
Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies evaluating its groundbreaking vector-based technology. According to the announcement, the data add to the body of evidence for HeartBeam’s key clinical indications, specifically arrhythmia and heart attack (myocardial infarction) detection, and showcase the technology’s pivotal role in advancing patient care. The studies were presented during the American Heart Association’s annual Scientific Sessions in Chicago, Nov. 16-18, 2024.
“The data presentations at AHA are a testament to HeartBeam’s dedication to building a robust body of clinical evidence to support our groundbreaking technology as we strive to make it easier for patients and physicians to monitor cardiac symptoms and seek timely diagnosis outside of a healthcare facility,” said HeartBeam CEO Robert Eno. “We thank our physician collaborators for their commitment to evaluating the value our technology can bring in different clinical situations and transform how cardiac conditions are managed in the future.”
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and four international issued patents related to technology enablement. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Calidi Biotherapeutics (NYSE American: CLDI) announced the successful closing of a public offering of 4,437,869 shares of common stock at $1.69 per share, raising approximately $7.5 million in gross proceeds. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering, which was conducted under an effective registration statement on Form S-3 filed with the SEC. The final prospectus is available on the SEC’s website or through Ladenburg Thalmann. The offering complies with all relevant securities laws and regulations.
Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN) announced new orders for its Mullen ONE Class 1 commercial EV cargo van from universities in Los Angeles and Berkeley, California, adding to recent orders from institutions like Princeton University, the University of Virginia, and the University of North Carolina. This growth reflects increasing adoption of clean energy vehicles by U.S. higher education institutions, which are prioritizing zero-emission goals for sustainability. Mullen’s commercial EVs, including the Mullen ONE cargo van and Mullen THREE cab chassis truck, are designed for efficiency and compliance with stringent environmental standards, aligning with the needs of these forward-thinking institutions. Incentives like the $7,500 Federal Tax Credit and state programs further enhance the affordability of Mullen’s vehicles for commercial fleet customers. CEO David Michery emphasized Mullen’s role in supporting universities’ sustainability efforts and enhancing campus operations.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
The successful calibration and benchmarking of the 4,400+ qubits Advantage2 processor is a significant milestone in D-Wave’s ongoing development of its sixth-generation annealing quantum computing system.
Advantage2 has significantly more computational power than the current Advantage(TM) system, able to solve certain customer problems 25,000 times faster.
Advantage2 offers improvements in areas such as faster time-to-solution, higher quality solutions, and ability to solve larger problems.
D-Wave (NYSE: QBTS), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, has achieved a significant milestone in the ongoing development of its sixth-generation annealing quantum computing system by completing the calibration and benchmarking of a 4,400+ qubit Advantage2 processor (https://ibn.fm/SEoTd).
The Advantage2 processor has shown substantial performance gains, with more computational power than the current 5,000 qubit Advantage system, as demonstrated by recent performance benchmarks. Advantage2 has been able to solve a wide range of complex computational problems in areas such as…
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
In recent years, cryptocurrency has captured the imagination of investors, who have embraced it as a revolutionary asset class offering high-growth potential. With Bitcoin and other digital currencies reaching new heights, many investors have turned to the crypto market as their hedge against inflation, government intervention and traditional assets. But there’s a time-tested asset that deserves more attention and has also been reaching all-time highs this year: gold.
Much like Bitcoin, gold’s scarcity is one of the key factors driving its value. The finite nature of both assets appeals to investors who are drawn to the idea of owning something limited in supply. Gold has long been a store of value, offering a hedge against the devaluation of fiat currencies. Its remarkable ability…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
Mullen Automotive (NASDAQ: MULN) announced that the California Air Resources Board (“CARB”) has approved Bollinger Motors’ all-electric Class 4 Bollinger B4 truck for the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (“HVIP”). Under HVIP, the Bollinger B4, priced at $158,758, qualifies for up to $60,000 in state vouchers, potentially reducing its cost to under $59,000 when combined with a $40,000 federal tax credit. The Bollinger B4 offers a 185-mile range and a 7,394-pound payload, catering to commercial fleets seeking sustainable and high-performing vehicles. This milestone aligns with Bollinger Motors’ efforts to expand its market presence, bolstered by recent production and regulatory achievements.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Brera Holdings (NASDAQ: BREA) analyzed recent Transfermarkt data showing significant growth in market values for Italian Serie B clubs and players between June and November 2024, underscoring the league’s competitive and developmental strengths. Notable club valuation increases include Pisa Sporting Club (+68.6%), Carrarese Calcio 1908 (+151%), and Cesena FC (+143.4%). Standout players like Rachid Kouda (+338%) and Tommaso Berti (+200%) have driven interest with exceptional performances. While some clubs, such as UC Sampdoria, face valuation declines, Brera emphasizes the long-term importance of youth development and talent refinement in Serie B, which remains a vital pathway for nurturing future football stars.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
NetworkNewsWire Editorial Coverage: Investment interest in the mining space is growing, driven by increasing demand for a wide range of metals that are becoming essential to modern industries. The push for clean-energy technologies, such as electric vehicles (“EVs”) and renewable energy systems, has amplified the need for critical minerals such as lithium, cobalt, nickel and rare earth elements. Meanwhile, traditional metals such as copper and aluminum are experiencing a resurgence due to their critical role in infrastructure and energy transmission. Gold and silver, as traditional stores of value, remain attractive amid economic uncertainties and inflationary pressures. Finally, the global transition toward decarbonization and energy efficiency is fueling demand for platinum group metals (“PGMs”), which are known for their purity, high melting points and unique catalytic properties. PGMs are vital in a number of industrial processes, technologies and commercial applications and play a critical role in autocatalysis and pollution control in the automotive sector. With potential supply constraints from key producing countries and geopolitical risks further tightening markets, mining companies are poised for growth. Platinum Group Metals Ltd. (NYSE: PLG) (TSX: PTM) (Platinum Group Metals Profile) is positioning itself as an emerging leader in the PGM sector through its flagship Waterberg Project in South Africa. Other mining and commodity related entities, including Sibanye Stillwater Limited (NYSE: SBSW), VanEck Junior Gold Miners ETF (NYSE: GDXJ), abrdn Physical Palladium Shares ETF (NYSE: PALL) and iShares Silver Trust (NYSE: SLV), are also seeing increased…
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
CNS Pharmaceuticals (NASDAQ: CNSP) announced that its abstract on the pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (“GBM”), has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology. The presentation, led by Chief Medical Officer Dr. Sandra Silberman, will provide updates on the randomized, controlled CNS-201 trial comparing Berubicin to Lomustine after first-line GBM therapy. The session will take place on Nov. 22, 2024, at the George R. Brown Convention Center in Houston, TX, during the Poster and Networking Session.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Calidi Biotherapeutics (NYSE American: CLDI) presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting highlighting its RTNova™ systemic virotherapy technology. This innovative platform leverages a tumor-selective vaccinia virus enhanced with extracellular enveloped viruses (“EEVs”) to overcome challenges like immune clearance and limited targeting in systemic virotherapy. RTNova demonstrated potential to target and kill metastatic tumor sites across multiple oncology indications, including metastatic lung cancer, while transforming tumor microenvironments and delivering therapeutic payloads. These findings position RTNova as a groundbreaking approach for addressing advanced metastatic diseases, supporting Calidi’s mission to develop multi-modal, off-the-shelf virotherapies for a broader patient population.
Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SOBRsafe, a provider of next-generation transdermal alcohol detection technology, just announced the launch of its fully integrated enterprise software solution
This solution is set to transform how health providers monitor and manage alcohol compliance, enhance responsiveness to treatment, reduce recidivism and provide hope for improved patient outcomes
SOBRsafe (NASDAQ: SOBR), a Colorado-based provider of next-generation transdermal alcohol detection technology, has just announced the launch of its fully integrated enterprise software solution that is expected to transform how health providers monitor and manage alcohol compliance. Designed to complement its software solution for point-of-care screening (SOBRcheck(TM)) and continuous monitoring (SOBRsure(TM)), this enterprise software is designed to enhance responsiveness to treatment, reduce recidivism and drive positive patient outcomes (https://ibn.fm/GGnkx).
According to SOBRsafe’s management, this software was the product of having dealt with inefficiencies in traditional methods used to monitor alcohol use. Such methods are often highly invasive and unhygienic, involving a sluggish manual reporting process that relies on printed records known to delay…
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
NextPlat (NASDAQ: NXPL, NXPLW) announced its participation in the 2024 China International Natural Health & Nutrition Expo (“NHNE”) in Wuhan, showcasing OPKO Health Europe products, including new veterinary and animal care offerings. Supported by its in-country marketing partner, NextPlat has seen increasing demand for OPKO products in China, fueled by online and offline promotional campaigns. The company is leveraging NHNE to connect with thousands of potential retail and distribution partners while launching OPKO storefronts on major Chinese platforms like WeChat and JD.com. NextPlat aims to secure broader physical distribution in major retail chains by 2025, advancing its strategy to capitalize on China’s vast health and wellness market.
NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.
NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent glioblastoma multiforme (“GBM”). Enrollment of 252 patients was completed, with primary analysis data expected in the first half of 2025. Berubicin, which crosses the blood-brain barrier, has received Fast Track and Orphan Drug Designations from the FDA. The company also licensed TPI 287, a late-stage candidate for brain malignancies, with plans for FDA engagement on future studies. CNS ended the quarter with $7.0 million in cash and additional funding, ensuring operations through Q2 2025.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN) announced a partnership with National Auto Fleet Group (“NAFG”) to sell its all-electric Class 4 Bollinger B4 commercial trucks to government agencies via NAFG’s Sourcewell-awarded contract. The Bollinger B4, designed with fleet and upfitter input, offers a 185-mile range, a payload of 7,394 pounds, and a robust chassis protecting its 158-kilowatt-hour battery pack. This collaboration provides Bollinger Motors with a streamlined pathway to secure government contracts, aligning with electrification goals of municipalities and agencies. Recent milestones for Bollinger include regulatory certifications, production launch, and multiple fleet agreements, bolstered by partnerships with key dealers, service centers, and battery suppliers.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Brera Holdings, an Ireland- and Italy-based, international holding company with a global portfolio of men’s and women’s sports clubs, remains committed to its mission to build shareholder value and deliver social impact programs through its teams
Its strategic investments have earned it a market cap of $10.04 million and an enterprise value of $9.21 million, with a presence across Europe, Asia and Africa
With a substantial revenue-generating opportunity in ticketing, media initiatives, digital content, live events, and merchandise sales, Brera Holdings continues to invest in both football and volleyball teams
So far, its efforts have earned it the 2024 Social Impact Through Soccer Award at IMPACT 5050
Brera Holdings (NASDAQ: BREA), a European-based international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach, is building shareholder value while also delivering social impact programs through its teams to their communities. Since its inception, the company has remained steadfast in building on the legacy brand of Brera F.C., efforts that have seen it spread beyond Europe to other continents.
According to Stock Analysis, today Brera Holdings has a market cap of $10.04 million and an enterprise value of $9.21 million (https://ibn.fm/1CXLW). This has been the product of strategic investment and a global sports portfolio that is growing and affirming the company’s ambition to become a…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a public offering with Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. Calidi has priced the offering of 4,437,869 shares at $1.69 per share, aiming to raise approximately $7.5 million in gross proceeds. Calidi intends to allocate the net proceeds toward working capital, general corporate purposes, and the advancement of pre-clinical and clinical trials for its targeted immunotherapy programs. The securities (excluding the warrants and the shares of common stock underlying the warrants) are being offered under an effective shelf registration statement, and the offering, subject to customary conditions, is expected to close around Nov. 15, 2024. Investors can access detailed information through the prospectus supplement and accompanying documents available on the SEC’s website or by contacting Ladenburg Thalmann.
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, visit the company’s website at www.calidibio.com.
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
NextPlat (NASDAQ: NXPL, NXPLW) reported Q3 2024 results reflecting the impact of its recent acquisitions, including Progressive Care and Outfitter Satellite, which contributed to consolidated revenues of $15.4 million. While healthcare revenue declined due to lower prescription reimbursement rates, e-Commerce revenue saw a 31% increase, largely from the Outfitter acquisition. The company recorded a net loss of $4.2 million due to increased expenses, including a non-cash impairment of Progressive Care’s intangible assets. Recent developments include expanding healthcare contracts and satellite communication device sales, along with a strengthened e-commerce presence in China and the UK. NextPlat projects ongoing growth from integration efficiencies and increased global demand in its healthcare and e-commerce sectors.
NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.
NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”) shared its Q3 2024 business results, highlighting continued advancements in commercial quantum computing. Key developments include NTT DOCOMO, Japan’s largest mobile phone operator, planning to deploy a D-Wave-powered network optimization solution, a collaboration with Japan Tobacco on drug discovery leveraging quantum with artificial intelligence (AI), and D-Wave’s designation as “awardable” on the US Department of Defense’s Tradewinds marketplace.
From a technology perspective, the company also completed calibration and benchmarking on a 4,400-qubit Advantage2™ processor, which is showing significant performance gains over the current Advantage™ system, the world’s largest quantum computer. D-Wave also introduced industry-leading service-level agreements for its LeapTM quantum cloud customers and outlined continued exploration of quantum-fueled AI architectures.
In addition, a new strategic partnership with Staque, a leading consulting and development practice in AI, blockchain and quantum computing, focused on the Middle East and corporate membership with the Chicago Quantum Exchange signal D-Wave’s expanding global footprint in quantum solutions for diverse industries.
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
SOBRsafe (NASDAQ: SOBR) has released SOBRsure™, a new wristband device that uses transdermal technology to detect alcohol levels through the skin, providing real-time monitoring to support sobriety and recovery. With a sleek, user-friendly design and GPS tracking, the device offers continuous alcohol detection, instant alerts, and the option to access historical reports through a premium subscription. CEO David Gandini emphasizes SOBRsure as both a technological breakthrough and a support system for individuals with alcohol use disorder, aiming to promote accountability and peace of mind for families, employers, and users. Available now, the wristband retails for $249, with subscriptions starting at $39.99 per month.
Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (“SOBRcheck”) and continuous monitoring (“SOBRsure”). SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Annovis provided business and financial updates for Q3 2024, spotlighting progress toward pivotal buntanetap trials in Alzheimer’s disease.
The FDA has cleared Annovis to proceed with a Phase 3 program, which will include a 6-month study to confirm buntanetap’s symptomatic benefits (beginning Q1 2025) and an 18-month study to explore potential disease-modifying effects.
Matthew Peterson, Ph.D., was appointed as Senior Clinical Scientist and will oversee quality and rigor in upcoming clinical trials.
Annovis filed three new patents for innovative combination therapies, involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), and a combination of all three.
As of Nov. 8, 2024, the company reported a cash position of $13.6 million, providing sufficient runway to support all Phase 3 preparatory activities and to initiate the pivotal Phase 3 Alzheimer’s study in Q1 2025.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), concluded the third quarter with significant milestones achieved and a clear path forward for its lead candidate, buntanetap.
Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and…
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
McEwen Mining (NYSE: MUX) (TSX: MUX) is positioned to benefit from increased investor interest in precious metals as well as growing demand for critical minerals. “McEwen Mining is a gold and silver producer with operations across the Americas, including Nevada, Canada, Mexico, and Argentina. In addition to its core business of precious metals, the company has significant exposure to copper through its 48% ownership of McEwen Copper, a subsidiary responsible for the advanced-stage Los Azules project in Argentina. Led by Rob McEwen, a seasoned mining veteran with a personal investment of $225 million, McEwen Mining is establishing itself as a significant player in the critical minerals space.”
“The company’s vision is simple: maximize asset productivity, improve profitability, and ultimately increase share value while offering returns to investors. With a seasoned leader at the helm, a diverse portfolio, and a keen focus on sustainability, McEwen Mining stands poised to unleash significant value, offering investors a golden opportunity to tap into an underappreciated gem.”
McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, it owns approximately 47.7% of McEwen Copper, which owns the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing its share price and providing a yield. Rob McEwen, MUX’s chairman and chief owner, has personally provided the company with $220 million and takes an annual salary of $1.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
Brera Holdings (NASDAQ: BREA), the only publicly traded multi-club ownership company in football, will attend Soccerex Miami 2024 on November 13 and 14. Celebrated as the premier event for football business, Soccerex provides Brera an opportunity to connect with clubs, leagues, investors, and other industry stakeholders. CEO Pierre Galoppi highlighted the event’s importance for staying attuned to global football trends and engaging with key figures across leagues, associations, and logistics teams. With Soccerex returning to Miami, Brera views the event as a valuable platform for fostering growth and visibility in the evolving football landscape.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for accelerated approval of CNM-Au8 for ALS, a 1-for-20 reverse stock split to meet Nasdaq requirements, an amended debt facility extending funding into Q2 2025, and a $7.3 million funding round. Clene’s Phase 3 RESTORE-ALS trial was presented in October, showcasing the company’s commitment to ALS treatment innovation. Financially, Clene ended Q3 with $14.6 million in cash and reported an $8.0 million net loss, reflecting decreased R&D and G&A expenses, but lower gains on warrant liability adjustments compared to 2023.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Brera Holdings (NASDAQ: BREA), the only publicly-traded multi-club football ownership company, has announced the continued achievements and future ambitions of Brera Tchumene FC, its Mozambique-based football club. Since its inception in 2023, Brera Tchumene FC has become a key player development force in Mozambique, achieving a place in the 2025 Moçambola, Mozambique’s premier league, after a 4-1 victory over Ferroviario de Namula. The club’s development initiatives include the formation of a women’s team, expansion of youth teams, and professionalized management. With ambitious growth plans, Brera Tchumene FC aims to capitalize on Mozambique’s untapped football potential and elevate player pathways to international leagues, enhancing the nation’s football standards and opportunities on the global stage.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
Mullen Automotive (NASDAQ: MULN) has listed its Class 1 electric cargo van, the Mullen ONE, on Turo, the world’s largest vehicle-sharing marketplace, to provide an efficient rental option for businesses with last-mile delivery needs. Florida-based Parasol Strategic Solutions is piloting the van in Jacksonville, Florida, citing a demand for compact, sustainable cargo transport in urban settings, with plans to expand the pilot to Baltimore, Maryland. The Mullen ONE, along with the Mullen THREE Class 3 EV, is part of Mullen’s commercial EV lineup, built for urban logistics and backed by federal and state incentives, providing significant cost savings for fleet customers.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” Scheduled for Nov. 13, 2024, Dr. Maccecchini’s presentation, titled “One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer’s and Parkinson’s Patients. A Potential Path for Lewy Body Dementia?” will explore the potential of Annovis’s lead drug candidate, Buntanetap, to address neurodegenerative diseases by enhancing cognitive and motor functions, with implications for Lewy body dementia treatment.
Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SOBRsafe (NASDAQ: SOBR) develops and sells a passive, preventative alcohol screening device called the SOBRcheck(TM) and a continuous alcohol monitoring wristband called SOBRsure(TM). “SOBRcheck is fitted with two sensors, one of which scans biometrics data from a user’s fingerprint, with the other detecting any alcohol excreted from the pores in the tip of the finger. The device is powered by the SOBRsafe software platform, which relays results in real time, improving employee throughput at point-of-care facilities. The SOBRsure(TM) device is equally configured to provide app-based reporting via the SOBRsafe platform, support GPS tracking and send removal alerts,” a recent article reads.
“In 2024, and consistent with our strategy, we have now established our technology, with our first revenue-generating customers in behavioral health growing to 35 accounts in the first and second quarters of this year. In addition, we entered the equivalent verticals in Australia and New Zealand and are gaining traction through a channel partner that we are very excited about. Finally, further international expansion is underway,” CEO Dave Gandini is quoted as saying.
About SOBRsafe(TM) Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (“SOBRcheck”) and continuous monitoring (“SOBRsure”). SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
The U.S. Department of Defense’s Chief Digital and Artificial Intelligence Office’s (“CDAO”) Tradewinds Solutions Marketplace is a comprehensive suite of tools and services for accelerating the procurement of emerging technologies by the Department of Defense (“DoD”).
D-Wave’s presence on the marketplace will enable DoD customers to more easily adopt the company’s annealing quantum computing technologies and solutions.
D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, has been deemed “Awardable” through the Department of Defense (“DoD”) Chief Digital and Artificial Intelligence Office’s (“CDAO”) Tradewinds Solutions Marketplace, a premier suite of tools and services for accelerating the procurement and adoption of emerging technologies (https://ibn.fm/POyFC).
The marketplace will now include D-Wave’s annealing quantum computing technology alongside other offerings like artificial intelligence (“AI”)/machine learning (“ML”), data, and analytics capabilities. Designating D-Wave an “Awardable” vendor will enable DoD customers to more easily adopt the…
NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial to evaluate symptomatic relief and an 18-month trial to assess disease-modifying potential, with the first study slated to start in Q1 2025. Financially, the company raised $12.7 million through its equity line of credit and $7.1 million from warrant exercises, securing its runway to enter Phase 3 trials. Annovis also strengthened its intellectual property with new patents for buntanetap combination therapies and expanded its team with the appointment of Senior Clinical Scientist Dr. Matthew Peterson to support trial quality and completion.
Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Cepton (NASDAQ: CPTN) shared updates for Q3 2024, highlighting advancements in its lidar technology commercialization, with a major long-range lidar RFQ in final stages with a Top 10 global automotive OEM. Cepton’s CEO, Jun Pei, noted the company’s solid positioning in the automotive lidar market, strengthened by a pending acquisition by Koito Manufacturing Co. Ltd. and continued development with OEMs for near-range lidar. The acquisition, set at $3.17 per share in an all-cash transaction, is anticipated to close in early 2025, subject to shareholder and regulatory approvals. For Q3, Cepton reported $0.5 million in revenue, with a GAAP net loss of $10.6 million and an adjusted EBITDA of $(8.0) million.
Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D-perception solutions across industries. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass-market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit metropolitan area. Cepton also has a presence in Germany to serve a fast-growing global customer base. For more information about this company, please visit www.Cepton.com.
NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”) recently participated in the Quantum Technologies Forum hosted by the University of Southern California (USC), presenting the latest advancements in its annealing quantum computing technology. D-Wave’s participation in the event highlights the company’s ongoing partnership with USC, which was the first organization to host a D-Wave Advantage™ quantum system in the United States in 2022.
Through D-Wave’s Leap™ quantum cloud service, USC’s Viterbi School of Engineering has leveraged this 5,000+ qubit system—the largest of its kind—for pioneering research in areas such as protein binding classification and quantum coherence. The forum, which convened experts across academia, industry, and government, aims to further quantum research and establish Southern California as a hub for quantum technology development.
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Mullen Automotive (NASDAQ: MULN) announced that Bollinger Motors has qualified for New York State’s New York Truck Voucher Incentive Program (“NYTVIP”), offering up to a $100,000 voucher for its all-electric B4 Truck. This incentive, provided by NYSERDA, marks the fourth state incentive for Bollinger in the Northeast, adding to similar programs in Massachusetts, New Jersey and Pennsylvania. Alongside a federal tax credit of $40,000 under the Inflation Reduction Act, Bollinger’s B4 Truck is primed to offer substantial financial incentives, bolstering its adoption in commercial fleets. Recent milestones for Bollinger include regulatory certifications, significant fleet orders and partnerships with dealers and service providers, underscoring the B4’s readiness for widespread deployment.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
John DiLullo and Rohit Ghai bring extensive leadership experience to D-Wave’s board to assist the company’s ongoing efforts to accelerate commercial quantum adoption and capitalize on its unique market position.
With a track record spanning more than 30 years in technology, including 15 years in cybersecurity and networking, DiLullo has held key executive positions with several leading companies.
Ghai brings years of experience working with both startups and large enterprises, with digital transformation expertise and knowledge across software, systems and security.
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, appointed two veteran technology industry leaders to its board of directors, supporting the increasing market adoption of the company’s annealing quantum computing solutions. The two new board members, John DiLullo and Rohit Ghai, join at a crucial time as the company is implementing an aggressive go-to-market strategy, aiming to accelerate quantum solution adoption across global businesses, research institutions and government agencies (https://ibn.fm/pQTJz).
DiLullo has an extensive track record spanning more than 30 years in technology, including 15 years in cybersecurity and networking. Bringing leadership expertise in growth and profitability transformation, DiLullo focuses on improving customers’ technology adoption experience, championing…
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, is increasingly bullish about the future of sports ownership
Over the past decade, the sports ecosystem has experienced nearly 430% returns across various leagues, attracting a diverse array of investors
The international football market alone is projected to grow to $4.6 billion by 2032, up from $3.3 billion in 2023
The company continues to grow its global sports portfolio while also leveraging social media to build its brand, as evidenced by the success of its recent partnership with global content creator THAADBOII Productions
Brera Holdings PLC (NASDAQ: BREA), an Ireland-based, international holding company rapidly expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach, believes the future of sports ownership is bright and full of potential. Owing to the growth of multi-club ownership and private equity, the company believes that the industry will continue to expand significantly, bringing in even more players with diversified cash flows, and growing various sports globally.
“The growth of multi-club ownership and private equity is revolutionizing sports,”noted Brera Holdings’ CEO, Pierre Galoppi. “We believe that as more companies engage and provide resources, clubs can advance to more competitive leagues, increasing revenues and valuations. Rising valuations and…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
HeartBeam (NASDAQ: BEAT), reported steady progress in its third quarter financial and operational results, advancing its cardiac care technology through key FDA 510(k) submissions and strategic leadership appointments. The company’s first FDA 510(k) submission for the HeartBeam system is actively under review, with HeartBeam responding to FDA inquiries and preparing for an Early Access Program post-clearance. Following this, HeartBeam plans to submit a second 510(k) application focused on its 12-lead ECG synthesis software. New CEO Robert Eno, along with other senior management hires, aims to guide the company toward U.S. commercialization. HeartBeam has also amassed significant clinical evidence supporting its innovative cardiac technology and recently garnered the “Rising Star” award in the Home Health Diagnostic Category at the Digital Health Hub Foundation Awards.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
McEwen Mining (NYSE: MUX) (TSX: MUX) has strengthened its support for Inventus Mining Corp. (TSXV: IVS) by acquiring 10,000,000 units in Inventus’s recently closed private placement, contributing $400,000 toward the $600,000 raised. Each unit in the placement includes one common share and one warrant, enabling further share purchases at $0.09 until 24 months post-closing, with potential for accelerated expiry if trading conditions are met.
McEwen’s significant investment demonstrates its commitment to advancing Inventus’s Pardo Project, marking a strategic alignment in McEwen’s broader investment interests in the precious metals sector.
McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, the company owns approximately 47.7% of McEwen Copper, which is developing the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing the share price and providing a yield. Rob McEwen, chair and chief owner, has a personal investment in the company of $220 million and takes an annual salary of $1. To learn more about the company, visit www.McEwenMining.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
Annovis Bio (NYSE: ANVS) has appointed Dr. Matthew Peterson as Senior Clinical Scientist, bolstering the team as it approaches pivotal Phase 3 trials for its neurodegenerative disease therapies, including treatments for Alzheimer’s and Parkinson’s disease. Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he specialized in therapies for peripheral nerve repair. With expertise in enhancing patient care and research experience with the Department of Veterans Affairs, he will focus on ensuring the scientific rigor and success of Annovis’ clinical trials for its lead drug candidate, buntanetap.
Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Two posters were presented by Annovis’ President and CEO, Dr. Maria Maccecchini, focusing on the company’s lead drug candidate buntanetap and its performance in clinical trials for the treatment of Alzheimer’s disease (“AD”).
A leading event for the Alzheimer’s research community, CTAD 2024, brought together key members of pharmaceutical companies, academic research centers, and patient advocacy groups to discuss avenues for AD treatment.
Buntanetap has been shown to significantly improve cognition in early AD patients, both ApoE4 carriers and non-carriers, and normalize biomarkers associated with AD pathology.
The company is preparing for Phase 3 clinical trials for buntanetap in early-stage Alzheimer’s patients: a 6-month study to confirm symptomatic benefits and an 18-month study to explore disease-modifying effects.
Annovis (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), presented two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference (https://ibn.fm/ysPFn), held between Oct. 29 and Nov. 1 in Marid, Spain.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
McEwen Mining (NYSE: MUX) (TSX: MUX) announced impressive financial results for Q3 2024, driven by a 36% increase in revenue to $52.3 million due to higher gold prices and an uptick in production. The company’s gross profit surged by 268% to $13.8 million, reflecting improved operational efficiencies and robust production levels. Additionally, McEwen Mining reported a reduced net loss of $2.1 million, significantly lower than the $18.5 million loss in Q3 2023. Operating cash flow rose to $23.2 million, while adjusted EBITDA soared 586% to $10.5 million, highlighting the company’s enhanced cash flow and operational gains across its assets.
McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, the company owns approximately 47.7% of McEwen Copper, which is developing the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing the share price and providing a yield. Rob McEwen, chair and chief owner, has a personal investment in the company of $220 million and takes an annual salary of $1. To learn more about the company, visit www.McEwenMining.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”) announced it has achieved “Awardable” status in the US Department of Defense’s (DoD) Tradewinds Solutions Marketplace, which showcases cutting-edge technologies for potential DoD adoption. This designation endorses D-Wave’s annealing quantum computing technology as a vetted solution for addressing complex challenges in logistics, manufacturing, scheduling, drug discovery, and sustainability. D-Wave collaborated with Clipper Defense to present use cases, including supply chain and transportation logistics optimization, highlighting the company’s potential to support DoD mission objectives.
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leading quantum computing company, will release its financial results for the third quarter of fiscal year 2024 ended September 30, 2024 on November 14, prior to market opening. Following the release, D-Wave will hold a conference call at 8 a.m. ET, featuring CEO Dr. Alan Baratz and CFO John Markovich, to discuss the financial results and provide insights into the company’s business outlook. Investors can join the call through the dial-in numbers provided via the press release.
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
CNS Pharmaceuticals (NASDAQ: CNSP), focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, a renowned neuro-oncologist and National Coordinating Investigator for CNS’s study on Berubicin. During the event, Professor Weller discussed the urgent need for effective treatments in glioblastoma multiforme (“GBM”), exploring how Berubicin could serve as a promising therapy within the current limited treatment landscape for this aggressive brain cancer.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Brera Holdings (NASDAQ: BREA) the only publicly traded multi-club ownership company focused on football, will participate in Sportico’s “Invest in Sports” Conference in New York City on November 4. Brera’s CEO Pierre Galoppi and Head of Investments Maria Xing will join prominent industry leaders, investors, and executives, including Blackstone’s David Blitzer and sports investor Alexis Ohanian, in discussing the evolving dynamics and growth of sports investments. The conference will cover how sports franchises have expanded into global brands across technology, finance, and real estate, while spotlighting rising sectors like women’s sports and youth athletics.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
McEwen Mining (NYSE: MUX) (TSX: MUX) will host a conference call on Wednesday, Nov. 6, 2024, at 11 a.m. EST to discuss its third-quarter 2024 financial results and provide updates on project developments. Following the management’s presentation, participants will have the opportunity to engage directly by asking questions over the phone during the live webcast, offering an interactive session to address investor inquiries and insights.
McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, the company owns approximately 47.7% of McEwen Copper, which is developing the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing the share price and providing a yield. Rob McEwen, chair and chief owner, has a personal investment in the company of $220 million and takes an annual salary of $1. To learn more about the company, visit www.McEwenMining.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
D-Wave Quantum (NYSE: QBTS) (“D-Wave”) has appointed technology leaders John DiLullo, CEO of Deepwatch, and Rohit Ghai, CEO of RSA, to its board of directors as the company executes an aggressive go-to-market strategy designed to drive the rapid adoption of its annealing quantum computing solutions across global businesses, research institutions and government agencies.
DiLullo and Ghai bring extensive expertise in accelerating growth and profitability, commercial technology adoption, and digital transformation. Their additions are strategically timed as D-Wave looks to leverage growth opportunities in fields like AI, logistics, and material science, underscoring its leadership in quantum computing.
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Brera Holdings (NASDAQ: BREA) celebrated UYBA’s resurgence in the Italian Serie A1 league with two successive victories. In their latest match, UYBA won a thrilling straight-set match against Chieri ’76 (25-22, 25-23, 25-23), following an earlier 3-1 triumph over Pallavolo Scandicci. Positioned 9th in the league, UYBA’s recent performances reflect renewed resolve as they aim to advance in one of Europe’s most storied women’s volleyball leagues, bolstered by Brera Holdings’ strategic support.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
Scinai Immunotherapeutics (NASDAQ: SCNI) will showcase its inflammation and immunology (“I&I”) product pipeline and contract development and manufacturing (“CDMO”) services at the BIO-Europe 2024 conference in Stockholm from November 4-6. CEO Amir Reichman and CTO Dr. Dalit Weinstein-Fischer will meet with potential clients, pharma partners and investors to discuss co-development opportunities in I&I, collaborations in dermatology, particularly for their Botox-like psoriasis treatment and Scinai’s CDMO capabilities. Scinai will also exhibit at booth #150, where interested parties can learn more about their end-to-end biologics services.
Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Brera Holdings (NASDAQ: BREA) updated fans on the early-season success of Brera Tiverija, its North Macedonian women’s football club, which leads the league with eight wins, one draw, and an impressive 47 goals scored. The team’s success is bolstered by local talent, with six players selected for the Senior National Team and two for the U19s, alongside Brera Tiverija’s head coach assisting national squads. Brera Holdings CEO Pierre Galoppi highlights the club’s focus on empowering young women through football, with aspirations to compete in the UEFA Women’s Champions League.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at http://ibn.fm/BREA
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
SuperCom (NASDAQ: SPCB), an electronic monitoring (“EM”) technology innovator, has developed an end-to-end solution that utilizes GPS tracking, communication, monitoring technologies, and real-time tracking and reporting to help justice systems worldwide reduce recidivism and improve offender rehabilitation. “SuperCom’s flagship platform works in near real-time to transmit information on a monitored subject’s whereabouts, not only on a geographical footprint but also with elevation data, for more effective use in the 3-D landscape inhabited by apartment dwellers and office workers,” a recent article reads. “The system also notifies victims via cell phone if an offender’s location is proximal to their location.”
Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, worldwide. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has inspired governments and national agencies to design and issue secure Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries, including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, and domestic violence prevention. For more information, visit the company’s website at www.SuperCom.com.
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. The company also introduced a new crystalline form of buntanetap with improved properties, “offering significant advantages over the less structured, old semi-crystalline form,” according to a recent article.
“Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received approval from the Food and Drug Administration to continue the clinical development with this new form of buntanetap. Additionally, the company was granted a U.S. patent for the use of buntanetap in the treatment of acute traumatic brain injury, expanding its coverage, since acute indication claims had been previously granted in Europe and worldwide,” the article reads. “These milestones position us strongly as we move closer to providing much-needed treatments to patients,” said Annovis Bio Founder, President and CEO Maria L. Maccecchini, Ph.D.
Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Mullen Automotive (NASDAQ: MULN) has announced that its subsidiary, Bollinger Motors, has delivered three Bollinger B4 electric trucks to TEC Equipment locations across Washington and California. The 2025 Bollinger B4, an all-electric Class 4 chassis cab truck built for commercial use, aims to support fleet electrification efforts on the West Coast, marking a milestone with TEC Equipment as a new dealer. These deliveries reflect a significant revenue contribution to Mullen’s fiscal quarter ending December 2024. The B4 model qualifies for up to $100,000 in federal and state tax incentives, strengthening Bollinger’s position in the EV commercial truck market and building on recent production and regulatory milestones.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Calidi Biotherapeutics (NYSE American: CLDI), a leader in oncolytic virotherapy (OV) for cancer, will feature in a RedChip Small Stocks, Big Money™ interview on Bloomberg TV on Oct. 26 at 7 p.m. ET. During the interview, Calidi’s Chief Business Officer, Stephen Thesing, provides an update on Calidi’s innovative approach, which uses engineered viruses to target and eliminate cancer cells. Calidi’s proprietary cell-based technology enhances the potency and longevity of these viruses by protecting them from immune response, boosting treatment efficacy. With IV-based and direct tumor administration methods, Calidi is advancing a new frontier in cancer treatment within the multi-billion-dollar oncology market.
Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Brera Holdings (NASDAQ: BREA), a publicly traded multi-club soccer ownership company, spotlighted the evolving landscape of sports ownership, where increased capital inflow from private equity, sovereign wealth funds, and high-net-worth individuals is driving growth. Citing a Goldman Sachs report, Brera emphasized the rising influence of multi-club ownership organizations like City Football Group and RedBird Capital, which leverage commercial and player-trading synergies. CEO Pierre Galoppi noted that growing private equity and corporate investments allow clubs to enter competitive leagues, enhancing revenue and valuation. As sports modernize, opportunities are expanding across media rights, stadium enhancements, apparel, and digital content, creating a dynamic, high-potential landscape for investors.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at http://ibn.fm/BREA
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
Mullen Automotive (NASDAQ: MULN) announced that Bollinger Motors founder, Robert Bollinger, has provided $10 million in non-dilutive debt financing to accelerate the production and sales of Bollinger’s all-electric Class 4 B4 truck. This funding supports Bollinger’s full-scale production efforts, with trucks now assembled by Roush Industries in Michigan, using over 70% U.S.-made content. Mullen CEO David Michery commended Bollinger’s continued commitment to building the brand, with more details on the financing to be filed in an upcoming Form 8-K with the SEC.
Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is set to present data on its innovative systemic antitumor virotherapy platform, RTNova (CLD-400), at multiple scientific conferences. These include the International Oncolytic Virotherapy Conference in Rotterdam (Oct. 27-30), the Immuno US 2024 in San Diego (Oct. 28-29), and the Society for Immunotherapy of Cancer Annual Meeting in Houston (November 6-10).
RTNova is designed to address the challenges posed by untargetable and untreatable metastatic diseases by targeting multiple tumor sites and altering the tumor immune microenvironment. This approach not only facilitates easier administration but also broadens the potential patient population who can benefit from this treatment.
“RTNova represents a groundbreaking advancement in cancer therapy, offering a systemic approach that enables us to target and treat metastatic tumors that were previously untouchable,” said Dr. Antonio F. Santidrian, Calidi’s Chief Scientific Officer who has been instrumental in advancing the development of the RTNova platform. “RTNova’s ability to fundamentally change the tumor microenvironment while delivering therapeutic viruses to multiple tumor sites has the potential to unlock new possibilities for patients facing some of the most challenging cancers. Ultimately, we believe RTNova has the potential to transform how we address previously untreatable metastatic diseases.”
Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
SuperCom (NASDAQ: SPCB) is leveraging its electronic monitoring (“EM”) platform as a cutting-edge solution that is ahead of the curve in what is still a niche market. Its client list in Europe and the United States is continuing to grow. EM technology is becoming increasingly popular among European governments to advance the social inclusion of criminal offenders through probationary services, reducing recidivism. The company recently announced $2.6 million in new orders from European governments.
“We are delighted to continue strengthening our collaboration with European governments,” said SuperCom President and CEO Ordan Trabelsi. “It highlights our leadership in the electronic monitoring sector and our ability to consistently meet our clients’ evolving needs. We remain committed to ensuring successful project execution and fostering lasting partnerships with governments worldwide… These repeat orders underscore our customers’ confidence in SuperCom’s cutting-edge technology and our unwavering commitment to improving public safety.”
Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, worldwide. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has inspired governments and national agencies to design and issue secure Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries, including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, and domestic violence prevention. For more information, visit the company’s website at www.SuperCom.com.
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
D-Wave’s Vice President of Quantum Technology Evangelism, Murray Thom, was a featured speaker at the event’s Technology Showcase, detailing how D-Wave quantum technologies can tackle complex optimization problems.
D-Wave’s Staff Technical Advisor Catherine Potts led an exhibitor workshop covering the fundamentals of quantum computing and demonstrated real-world cases.
Participants were given the opportunity to explore D-Wave’s Leap(TM) real-time quantum cloud service, which features a portfolio of hybrid solvers able to deal with problems involving millions of variables and constraints.
The 2024 INFORMS Annual Meeting was expected to attract 6,000 attendees, including members, students, prospective employers and employees, as well as academic and industry experts.
D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, recently participated in the 2024 INFORMS Annual Meeting, highlighting its quantum optimization solutions and customer success stories.
INFORMS is the largest professional association for the decision and data sciences, encompassing a diverse range of academic and industry experts in operations research, analytics, management science, economics, behavioral science, statistics, artificial intelligence, data science, applied mathematics, and…
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Israel-based SuperCom is promoting public safety founded on the strength of its superior electronic monitoring (“EM”) technology platform
SuperCom’s PureSecurity platform uses GPS to track the movements of individuals monitored by law enforcement on pretrial and probationary release from jail custody, including a 3-D elevation blueprint that is useful to apartment dwellers and office workers
The importance of GPS-enabled tracking was highlighted in a recent New York State domestic violence case that reportedly led to a woman’s death when her accused attacker was freed from GPS monitoring
The PureSecurity platform not only alerts supervising law enforcement about an EM-monitored individuals’ movements, but also provides alerts via cell phone to potential victims to help them seek safety in a timely manner
Behind the crime statistics related to domestic violence, and efforts to provide a supportive society to its victims, are personal stories of fear and loss, as exhibited by the son of a domestic violence victim who told the judge during a court hearing for the suspect that “I’d rather have my mom back more than anything — that’s all that really matters more than anything.”
Less than a week before his mother’s death, the suspect, who had previously been accused of assaulting her, was released from electronic monitoring after a judge noted that the ankle monitor in use did not include GPS tracking, despite the court having access to…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities purchase agreements with institutional investors to raise approximately $3 million. The funding will come from the sale of 17,647,060 shares of common stock, priced at $0.17 per share, in a registered direct offering. The proceeds will be used for general corporate purposes and working capital. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction, which is expected to close today, Oct. 24, 2024, pending customary conditions.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, was recognized with the 2024 Digital Health Hub Rising Star award in the ‘Home Health Diagnostic’ category at the HLTH global healthcare conference. The award highlights HeartBeam’s innovative vector-based technology, which captures heart electrical signals in three dimensions to provide detailed cardiac insights. CEO Rob Eno emphasized the importance of timely care in cardiac health, praising the team’s efforts in developing a cable-free, credit card-sized ECG device, currently under FDA review, as a step towards personalized, AI-driven cardiac care.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently announced an upcoming meeting with U.S. Food and Drug Administration (“FDA”) leadership. The focus is to discuss Clene’s CNM-Au8® biomarker and related clinical and survival data for ALS. “FDA’s Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 (‘DN1’) review team, as well as recognized key opinion leaders in ALS, biostatistics and biomarkers,” will attend the meeting according to a recent article.
“Clene looks forward to the opportunity to have experts present their views to the FDA and address questions on ALS biomarkers, related clinical endpoints and survival data, all of which Clene believes are essential for the understanding of its CNM-Au8,” the company stated in a news release. Clene also voiced appreciation for the FDA’s use of process and regulatory flexibility to obtain the best outcome for people living with ALS.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Annovis Bio received FDA clearance to move forward with Phase 3 trials for buntanetap following an End-of-Phase 2 meeting on October 10, 2024.
The pivotal trials will investigate buntanetap’s short-term symptomatic effects and potential long-term disease-modifying benefits in early-stage Alzheimer’s disease (“AD”) patients.
Annovis Bio is targeting potential NDA submission within one year of the study’s initiation for symptomatic treatment, based on the results of a well-executed 6-month trial.
The FDA raised no safety concerns regarding buntanetap and supported the use of its new crystal form in development.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently announced a significant milestone in its drug development process. On October 10, 2024, the company held an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap.
Phase 3 Clinical Trials Overview:
A 6-month study to confirm buntanetap’s symptomatic effects in early-stage AD patients.
An 18-month study aimed at evaluating its long-term potential as a disease-modifying treatment.
The first, 6-month study is slated to begin in Q1 2025. Notably, if the initial 6-month study yields positive results, it may support an NDA submission of buntanetap as a symptomatic treatment within a year of…
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
Artificial intelligence is rapidly reshaping the landscape of economies around the world. Estimates indicate that generative AI alone will triple its growth to a total market value of $1.3 trillion in the next decade.
As most investors know by now, there is a surge in the demand for energy-guzzling data centers that are designed to develop and train AI systems. They also know that advanced semiconductor chips are at the heart of all AI technologies. However, many haven’t considered that critical minerals, such as…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
SOBRsafe (NASDAQ: SOBR) has introduced an enterprise software platform that integrates its transdermal alcohol detection technologies, SOBRcheck and SOBRsure, into a streamlined dashboard for health providers. The system allows real-time monitoring of alcohol compliance across multiple users and locations, addressing inefficiencies in current testing methods. By offering instant, non-invasive detection of alcohol through the skin, the software aims to enhance treatment outcomes and improve organizational efficiency in behavioral health centers. The platform’s historical data tracking also aids compliance verification with third parties.
Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (“SOBRcheck”) and continuous monitoring (“SOBRsure”). SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Annovis Bio (NYSE: ANVS) will showcase its latest scientific findings on its Alzheimer’s drug candidate, Buntanetap, at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid from Oct. 29 to Nov. 1, 2024. The company will present two posters highlighting Buntanetap’s efficacy in early Alzheimer’s patients and its impact on reducing neurotoxic proteins, improving axonal integrity, and enhancing neuronal function. These results further support Annovis Bio’s ongoing efforts to develop transformative therapies for neurodegenerative diseases.
Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
SuperCom (NASDAQ: SPCB), a leader in e-Government, IoT, and Cybersecurity solutions announced that its president and CEO, Ordan Trabelsi, will present a corporate overview and meet with investors at the Annual LD Micro Main Event in California. The presentation is scheduled for Oct. 30, 2024, at 2 p.m. PT. Trabelsi will provide insights into the company’s operations and growth strategies during the event.
The company invites interested parties to register to one-on-one meetings or watch the presentation virtually here: https://ibn.fm/CjSMk.
Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification, and security solutions to governments and organizations, both private and public, worldwide. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has inspired governments and national agencies to design and issue secure Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries, including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, and domestic violence prevention. For more information, visit the company’s website at www.SuperCom.com.
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Brera Holdings (NASDAQ: BREA), a multi-club football ownership company, has enlisted IBN to lead its corporate communications efforts. Brera Holdings focuses on expanding its global portfolio of sports clubs, particularly in emerging markets across Africa, Asia, and Europe, while unlocking value through revenue streams such as sponsorship deals and transfer fees. Leveraging IBN’s extensive investor-focused distribution network, the partnership aims to boost awareness of Brera’s innovative multi-club strategy and its socially impactful initiatives.
Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.
NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at http://ibn.fm/BREA
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
SOBRsafe (NASDAQ: SOBR), the developer of advanced transdermal alcohol detection and monitoring technology, launched a national campaign targeting behavioral health providers. “SOBRsafe is undertaking the campaign in partnership with prominent national agencies drawn from the public relations and digital and social media marketing spaces. The campaign seeks to introduce the SOBRsafe(TM) technology to a large and growing market, and is designed to capture over 4 million projected views over the next year and present the technology to more than 45,000 behavioral health decision makers… The SOBRsafe(TM) technology is a scalable, patent-pending software platform, which integrates with the company’s non-invasive devices, the SOBRcheck(TM) and SOBRsure(TM), to produce statistical, measurable user and business data,” a recent article reads.
“Consistent with our strategy, we established our technology in the behavioral health vertical with our first revenue-generating customers in 2024. We are working with national communications leaders to build the SOBRsafe brand, grow demand and gain market share. This effort will move us closer to improving patient outcomes and saving lives,” said SOBRsafe CEO and Chairman Dave Gandini.
Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (“SOBRcheck”) and continuous monitoring (“SOBRsure”). SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Israel-based SuperCom has secured a new five-year contract for deploying its electronic monitoring tracking technology in the company’s home country, working with the Israel Prison Service state agency
The contract will help the agency monitor an estimated 1,500 enrolled offenders
SuperCom has been reporting an increasing number of contract wins in Europe and the U.S. this year to help public safety agencies track the movements of low-risk offenders
Electronic monitoring programs are increasingly welcomed in nations working to reduce criminal recidivism and provide safety to domestic violence victims, helping agencies reduce their incarceration costs in the process
Electronic monitoring (“EM”) technology innovator SuperCom (NASDAQ: SPCB) recently secured a new contract with the Israel Prison Service state agency (“IPS”) to provide full-service EM capabilities for all electronically monitored criminal offender programs throughout the country.
SuperCom won the contract, already underway, in partnership with a nationwide security services provider through a competitive process that included several rounds of negotiations, demonstrations and…
NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Clene gave a fireside presentation and held one-on-one investor meetings at the 2024 Maxim Healthcare Virtual Summit on October 15.
On October 30, Clene will give a presentation and participate in one-on-one meetings at The ThinkEquity Conference 2024 at the Mandarin Oriental Hotel in New York.
Clene’s lead drug candidate, CNM-Au8® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions.
Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS and is scheduled to have a meeting with the FDA leadership in November.
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) multiple sclerosis (“MS”) and Parkinson’s Disease (“PD”), is participating in two top investor conferences this month to present its latest achievements and key updates on its lead drug candidate, CNM-Au8 (https://ibn.fm/BDqtM).
On October 15, the company gave a fireside presentation at the 2024 Maxim Healthcare Virtual Summit. The October 15-17 event included presentations and interactive discussions with CEOs and key executives from a wide range of biotechnology, diagnostic, medical device, and healthcare information technology…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
D-Wave has introduced service-level agreements (“SLAs”) for customers of its Leap quantum cloud service who are moving applications into production
The Leap quantum cloud service offers 99.9% availability for its Solver API and aggregated set of annealing quantum computers
The Leap quantum cloud service has seen a surge in usage over the past 12 months, with more than 60 million jobs submitted, a 215% increase over the previous 12 months
D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, has introduced service-level agreements (“SLAs”) tailored for customers of its Leap quantum cloud service who are moving applications into production. According to a company news release, this move confirms D-Wave’s confidence in the Leap service’s availability, reliability, scalability, and ability to support commercial-grade quantum and hybrid-quantum application requirements (https://ibn.fm/mTrP0).
“As the transition to production deployments accelerates, providing exceptional access to our cloud service has never been more critical,” said Dr. Trevor Lanting, chief development officer at D-Wave. “Our SLA offering is designed to support this dynamic shift with confidence, enabling businesses to thrive as…
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Brera Holdings recently announced that it has signed an exclusive letter of intent to acquire an Italian second division soccer club in the Serie B pro league
The company previously commissioned a valuation analysis that discusses Brera management’s intention to acquire professional soccer teams
A conservative scenario contained in the analysis projects one-year 10x potential revenue growth, with accompanying implied share value increases, for Brea should it complete the potential acquisition
A best-case scenario, in which Brera acquires a second soccer club, projects a jump in revenue of over 20x one-year post acquisition
The report concludes by emphasizing that Brera’s future appears promising
Brera Holdings (NASDAQ: BREA) announced in September 2024 that it had signed an exclusive letter of intent to acquire another professional soccer team, this one in Serie B, the Italian second division. The company is now completing due diligence for the potential acquisition. A previously conducted investment valuation analysis (https://ibn.fm/QFukR) details the potential impact of this acquisition, and possibly others, on Brera’s revenue and valuation metrics.
The analysis, authored by S. Czerwenka, CFA, considers two potential acquisition scenarios, one conservative and the other a best case. The conservative scenario projects that should the company complete this potential acquisition or one like it, described as acquiring an…
NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
HeartBeam (NASDAQ: BEAT) has appointed Robert Eno as its new chief executive officer, effective Oct. 21, 2024. Eno, who joined the company as President in January 2023, will focus on guiding HeartBeam through FDA 510(k) clearance and preparing for commercialization of its transformative vector-based cardiac technology. Founder and current CEO, Dr. Branislav Vajdic, will transition to president, concentrating on advancing the company’s innovative technology and artificial intelligence applications. HeartBeam’s technology captures the heart’s electrical signals in three dimensions and aims to revolutionize cardiac care with a credit card-sized device capable of synthesizing a 12-lead ECG. With extensive experience in MedTech and strategic growth, Eno is expected to position the company for continued success.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Brera Holdings is the only publicly traded company focused on multi-club ownership of international football teams.
As of October 2024, the company owns full or majority stakes in three professional soccer clubs across Europe, Asia and Africa, as well as an Italian professional volleyball club.
In September 2024, Brera Holdings received the prestigious Social Impact Through Soccer award from the Internet Marketing Association for the second time in three years, recognizing its global social contributions through football.
In January 2024, the company announced a proactive search to acquire an Italian Serie B football club, targeting expansion into Italy’s second division. A recent CFA report has projected significant revenue growth and capital appreciation for Brera upon completion of this acquisition.
In June 2023, Brera Holdings acquired a strategic stake in English Premier League club Manchester United PLC, later selling the stake for a 74% profit, highlighting its ability to capitalize on high-value football investments.
Brera Holdings (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.
Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the…
NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Gold has been surging in popularity and value. Just this year, the precious metal has increased by approximately 28%, reaching a peak of more than $2,680 per ounce. In addition to Federal Reserve rate cuts and central bank purchases across emerging markets, the prospect of new financial sanctions imposed by the U.S. and growing concerns about the national debt could provide additional momentum for gold as many analysts forecast prices will continue to set new all-time highs.
In the current market landscape, gold stands out as a strategic hedge against both geopolitical and financial risks, making it an attractive option for investors seeking stability and potential growth in an uncertain economic climate. With its combination of rising demand and strong…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), announced today that the U.S. Food and Drug Administration (“FDA”) has granted clearance to proceed with pivotal Phase 3 studies for buntanetap in early-stage Alzheimer’s patients. This decision follows a successful End-of-Phase 2 meeting held on Oct. 10, 2024, where Annovis and the FDA aligned on the next steps for advancing buntanetap toward New Drug Application (“NDA”) submissions.
The Phase 3 program will consist of two trials: a 6-month study aimed at confirming buntanetap’s symptomatic benefits and an 18-month study to explore potential disease-modifying effects. The company plans to initiate the first trial in Q1 2025, with the possibility of submitting an NDA based on the completion of the 6-month study.
“We are grateful for the FDA’s support in advancing our Phase 3 studies as planned,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. “This clearance marks an important step forward as we work to bring buntanetap to patients in need. Our team is preparing to launch the study early next year, and we will provide ongoing updates as we progress towards our goals.”
In the company’s previous Phase 2/3 study, buntanetap demonstrated significant cognitive improvements in early Alzheimer’s patients, while maintaining a strong safety profile. These positive results informed the Phase 3 trial design, positioning the company to further validate buntanetap’s efficacy and safety in a larger patient population.
Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
